China Pharmaceutical University and Chongqing Innovation Institute, China Pharmaceutical University have identified compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, fibrosis, infections, inflammation, autoimmune diseases, metabolic disorders, neurological disorders and cardiovascular disorders, among others.
Zhejiang Yangli Pharmaceutical Technology Co. Ltd. has synthesized thiazole-substituted pyrimidine amine compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.
Hypoxic pulmonary hypertension (HPH) is a condition characterized by increased pulmonary artery pressure caused by prolonged exposure to a hypoxic environment. It frequently occurs among individuals residing at high altitudes and those with chronic obstructive pulmonary disease.
Abilita Therapeutics Inc. has developed a novel approach targeting CCR8 – ABT-863 – that works as a potent inverse agonist to block CCL1-dependent and basal receptor signaling.
Vycellix Inc. has successfully completed preclinical development for its universal cell engineering platform (VY-UC) and will now seek clinical trial clearance in Sweden to begin a phase I study of VNK-101, an allogeneic natural killer (NK) cell therapy engineered with VY-UC for relapsed or refractory multiple myeloma.
LRRK2 plays a key role in the biology of multiple neurodegenerative disorders, including Parkinson’s disease (PD) and progressive supranuclear palsy (PSP), where mutations or altered activity are associated with impaired cellular signaling and neuronal decline.
Previous findings have shown that the bisteric mTORC1 inhibitor Rapalink-1 exerts superior efficacy than the parent inhibitors rapamycin and sapanisertib in orthotopic xenograft models of glioblastoma. The bitopic clinical derivative of this compound is RMC-5552 from Revolution Medicines Inc., which is currently in phase I/II clinical studies for glioblastoma.
Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies.
Animate Biosciences Inc. has released new preclinical results demonstrating that AI-designed peptides generated by its Animateiq discovery platform significantly reduced hallmark inflammation and fibrosis signals across multiple human cell types, including skin, lung, heart and liver.
RSS
